Startseite » Forschung » Studien Finasterid » Hirshburg (2016). Adverse Effects and Safety of 5-alpha Reductase Inhibitors. A Systematic Review
vmPFC
Hirshburg (2016). Adverse Effects and Safety of 5-alpha Reductase Inhibitors. A Systematic Review [Beitrag #375059] :: Mi., 19 Oktober 2016 21:06
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023004/

Abstract
Finasteride and dutasteride, both 5-alpha reductase inhibitors, are considered first-line treatment for androgenetic hair loss in men and used increasingly in women. In each case, patients are expected to take the medications indefinitely despite the lack of research regarding long-term adverse effects. Concerns regarding the adverse effects of these medications has led the United States National Institutes of Health to add a link for post-finasteride syndrome to its Genetic and Rare Disease Information Center. Herein, the authors report the results of a literature search reviewing adverse events of 5-alpha reductase inhibitors as they relate to prostate cancer, psychological effects, sexual health, and use in women. Several large studies found no increase in incidence of prostate cancer, a possible increase of high-grade cancer when detected, and no change in survival rate with 5-alpha reductase inhibitor use. Currently, there is no direct link between 5-alpha reductase inhibitor use and depression; however, several small studies have led to depression being listed as a side effect on the medication packaging. Sexual effects including erectile dysfunction and decreased libido and ejaculate were reported in as many as 3.4 to 15.8 percent of men. To date, there are very few studies evaluating 5-alpha reductase inhibitor use in women. Risks include birth defects in male fetuses if used in pregnancy, decreased libido, headache, gastrointestinal discomfort, and isolated reports of changes in menstruation, acne, and dizziness. Overall, 5-alpha reductase inhibitors were well-tolerated in both men and women, but not without risk, highlighting the importance of patient education prior to treatment.




Fin seit 2009 (1.25mg/Woche); Minox seit 2011; Ket seit 2012 (1%/Tag)
Abgesetzt: Dut 2011-2017 (0.05mg/Woche); RU 2014-2017 (3%/Tag)

Den Beitrag einem Moderator melden

 Eine private Nachricht an diesen Benutzer verschicken  
 
[Beitragsindex]
 
Gelesene Nachricht
Vorheriges Thema: Singh (2014). Persistent Sexual Dysfunction and Depression in Finasteride Users for Male Pattern...
Nächstes Thema: Ali et al. (2015). Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with...
Gehe zum Forum:
  

[ Themen als Syndikate anderen Seiten zur Verfügung stellen (XML) ] [ RSS ] [ PDF ]

aktuelle Zeit: Sa. Dez 06 20:55:01 MEZ 2025

Insgesamt benötigte Zeit, um die Seite zu erzeugen: 0.08971 Sekunden
Letzte 10 Themen



Videos / Infos
Video Schuppen / seborrhoisches Ekzem


Partner Hairforlife FUE EUROPE
» Neurodermitis :: » ADS (ADHS) :: Impressum / Datenschutz
.:: Kontakt :: Forumsindex ::.

Betrieben mit: FUDforum 3.1.3.
Copyright ©2001-2023 FUDforum Bulletin Board Software